Generate Biomedicines
PublicGenerate Biomedicines is now publicly traded
The data on this page reflects Generate Biomedicines's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Feb 27, 2026
Last Round
Corporate Funding
Dec 18, 2024
Total Funding Raised
$1.11B
Company Overview
Generate Biomedicines operates in Biotech and is based in Somerville, Massachusetts. Its recorded funding history includes a Corporate Funding round in December 2024.
Generate Biomedicines is a biotechnology company that utilizes a generative biology platform to create innovative drugs across various protein modalities and therapeutics.
Sector
Biotech
Verticals
Artificial Intelligence & Machine Learning, HealthTech, Life Sciences
AI Layer
Application
Generate Biomedicines Comparables
Compare Generate Biomedicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AbSci | 87% | |
| Chai Discovery | 84% | |
| Insilico Medicine | 83% |
For institutional investors. Book with your work email.
Generate Biomedicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Feb 27, 2026 | ||||
| Corporate Funding | Dec 18, 2024 | ||||
| Corporate Funding | Sep 24, 2024 | ||||
| Series C | Sep 14, 2023 | ||||
| Series B | Nov 18, 2021 | ||||
Series A | Sep 10, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Generate Biomedicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Human Capital | Series B |
| Pictet Group | Series C |
| Mirae Asset | Series C |
| Guggenheim Securities | IPO |
| Altitude Life Science Ventures | Series B, Series C |
| MAPS Capital Management | Series C |
| Morningside Ventures | Series B, Series C |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- has_lossNov 12, 2026
Generate Biomedicines reports a $87.7M loss in Q3 2026, or 68 cents per share, in Massachusetts on Nov 12th '26.
- attends_eventNov 9, 2026
Generate Biomedicines attends guggenheim conference.
- adopts_technologyOct 28, 2026
Generate Biomedicines uses Claude Code to build an agent harness that orchestrates LLM reasoning and computational tools with a focus on structured outputs and observability.
- is_developingOct 28, 2026
Generate Biomedicines develops the shorter genetic instructions with Claude for CAR T-cell therapy being explored to treat solid tumours; one design is about 70% shorter and enables immune cells to produce roughly 10 times as many receptors in laboratory tests.
- is_developingOct 28, 2026
Generate Biomedicines is working with Claude Code to adapt CAR T-cell therapy, traditionally used against blood cancers, for solid tumours; laboratory tests show the redesigned genetic instructions increase receptor production and improve immune-cell activity in Nov '26.
For institutional investors. Book with your work email.
Generate Biomedicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.